Marking a significant structural shift for India’s digital health landscape, Tata 1mg has turned EBITDA positive across all its established business units for the fiscal year 2025-26.

The announcement represents a key corporate milestone for the Tata Digital-backed company, proving that large-scale healthtech applications can move past cash-burn strategies toward self-sustaining unit economics. According to the company, the bottom-line shift reflects the compounding advantages of an integrated, omnichannel healthcare ecosystem that has been scaled over the past decade.

Co-founder and Chief Executive Officer Prashant Tandon stated that the company’s core operations reached an inflection point in December, maintaining robust EBITDA-positive momentum through the entire fourth quarter.

The Growth Engine: Diagnostics Crosses ₹600 Crore ARR

The primary driver behind the platform’s financial turnaround was a massive surge in its diagnostics division, which successfully stepped up to become a core profit generator:

• Revenue Velocity: The diagnostics vertical crossed an annualized revenue run rate (ARR) of more than ₹600 crore during the fiscal year.
• Growth Metrics: The division logged a blistering 40% year-on-year growth rate.
• Margin Cushion: Crucially, this hyper-growth was achieved while consistently maintaining stable, double-digit EBITDA margins.

To support this volume, Tata 1mg expanded its infrastructure to operate 19 National Accreditation Board for Testing and Calibration Laboratories (NABL)-accredited labs serving over 70 Indian cities. Additionally, its National Reference Lab secured premium international quality certification from the College of American Pathologists (CAP).

Performance Across Alternative Verticals

Beyond the diagnostics infrastructure, Tata 1mg’s other primary business arms demonstrated parallel structural improvements throughout the year:

• ePharmacy Breakeven: The company’s core online pharmacy wing officially achieved operating breakeven. The unit is simultaneously rolling out hyper-local express deliveries, offering 30-to-60-minute medicine drops across 10 major cities.
• Speciality Pharma Surge: The specialized pharmaceutical care wing—which covers high-ticket patient-support programs, oncology care, adult vaccinations, and obesity management—expanded by roughly 65% during FY26.
• D2C Wellness Profitability: The direct-to-consumer health products division successfully cleared a ₹200 crore ARR milestone while remaining strictly profitable on a standalone basis.

Going Omnichannel: The 500-Store Roadmap

To hedge against rising digital customer acquisition costs, Tata 1mg is actively executing a massive brick-and-mortar physical retail strategy.

The company has already scaled its physical footprint to over 280 retail stores distributed across nine geographic clusters. Over the next 12 months, management plans to double this presence to more than 500 physical stores. This hybrid layout allows the brand to seamlessly fulfill online medicine orders, host localized walk-in customers, and act as localized mini-hubs for at-home diagnostic sample collections.

Alongside consumer-facing additions, the firm has turned its attention toward institutional software-as-a-service (SaaS) revenue. Its proprietary, AI-powered healthcare intelligence platform, Pulse, is now actively utilized by over 75 major pharmaceutical companies to extract data-driven market insights.

By successfully converting scale into optimized unit economics across pharmacy, diagnostics, and B2B health intelligence, Tata 1mg has effectively broken the industry-wide stereotype that e-pharmacies are perpetual loss-making ventures.